NCT05751941View on ClinicalTrials.gov

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 14, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Prostate CancerMetastatic Prostate Cancer
Interventions
DRUG

Abiraterone

1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily

DRUG

Enzalutamide

160 mg of Enzalutamide will be given orally daily ending at week 4

DRUG

Apalutamide

240 mg of Apalutamide will be given orally daily ending at week 4

DRUG

Sipuleucel-T

Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Dendreon
All Listed Sponsors
collaborator

Dendreon

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER